MedTrace Logo

ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery

NCT04695522 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-01-05

No results posted yet for this study

Summary

Ischemic cardiomyopathy undergoing coronary artery bypass surgery

Conditions

  • D017202

Interventions

BIOLOGICAL

ADR-002K administration

ADR-002K administration

Sponsors & Collaborators

  • Rohto Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Osaka University

    lead OTHER

Principal Investigators

  • Daisuke Mori, Ph.D · Osaka University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-27
Primary Completion
2021-04-30
Completion
2021-10-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04695522 on ClinicalTrials.gov